Effects of ions on thyrotrophin and prostaglandin E stimulation of glucose oxidation and adenyl cyclase-cyclic AMP system in dog thyroid slices.

K. Yamashita,G. Bloom,J. Field

DOI: https://doi.org/10.1016/0026-0495(71)90015-1

1971-10-01

Abstract:

What problem does this paper attempt to address?

[Expression of Human VEGF165 Gene in Rat Bone Marrow Stromal Cells in Vitro].

Xiao-feng Bai,Wei-dong Tian,Xi-zhe Chen,Zhi-yong Li

DOI: https://doi.org/10.3969/j.issn.1672-173x.2005.04.005

2005-01-01

Abstract:OBJECTIVE:The purpose of this study was to evaluate the feasibility of VEGF165 gene transfection into bone marrow stromal cells and make the groundwork of VEGF gene therapy for the revascularization of bone tissue engineering.METHODS:Bone marrow stromal cells (BMSC) were cultured in vitro, and were tested for the dexamethasone-induced potential to form mineralized-like tissue in culture in the presence of ascorbic acid and beta-glycerophosphate. The vector pcDNA3.1-VEGF165 was transfected into bone marrow stroma cells with the method of liposome mediated or Sofast transfectam reagent. The expression level of human VEGF165 in the transformed cells was detected by immunocytochemistry.RESULTS:The percent of the positive cells after VEGF165 gene transfection mediated by liposome and cationic polymer was 11.34 and 11.42 respectively. There was no significant difference in gene transfer efficacy between liposome and cationic polymer mediated gene delivery. While the percent of the number of survival cells after gene transfection was 74.60 and 85.88 respectively, the cytoxity of liposome was a little higher than that of cationic polymer.CONCLUSION:The experiment demonstrated that rhVEGF165 was successfully expressed in BMSC. This result could serve as a basis for the next step of revascularization of bone tissue engineering.
Cracking the ENCODE: From transcription to therapeutics

G. Mehta,R. Jalan,R. Mookerjee

DOI: https://doi.org/10.1002/hep.26449

IF: 17.298

2013-06-01

Hepatology

Abstract:The human genome encodes the blueprint of life, but the function of the vast majority of its nearly three billion bases is unknown. The Encyclopedia of DNA Elements (ENCODE) project has systematically mapped regions of transcription, transcription factor association, chromatin structure and histone modification. These data enabled us to assign biochemical functions for 80% of the genome, in particular outside of the well-studied protein-coding regions. Many discovered candidate regulatory elements are physically associated with one another and with expressed genes, providing new insights into the mechanisms of gene regulation. The newly identified elements also show a statistical correspondence to sequence variants linked to human disease, and can thereby guide interpretation of this variation. Overall, the project provides new insights into the organization and regulation of our genes and genome, and is an expansive resource of functional annotations for biomedical research.
Tumor Imaging: Radiation Oncology Perspective

N. Mayr,S. Lo,J. Grecula,Jian Z. Wang,Hualin Zhang,J. Montebello,Douglas D. Martin,W. Yuh

DOI: https://doi.org/10.1097/01.rmr.0000245462.28525.51

2006-04-01

Abstract:BACKGROUND Until 30 years ago, radiation oncology, previously known as therapeutic radiology, was one of the subspecialties of radiology. It was an era in which radiation therapy planning was performed using plain radiograph images and clinical setups. After the rapid growth and developments within the specialty, most radiation oncology divisions became independent departments. With the development of modern image-based treatment planning, diagnostic imaging has now become an integral part of radiation oncology. One of the most important factors impacting treatment outcome is the amount of radiation that can be safely be delivered to the tumor (target). This is often limited by the radiation tolerance of critical structures, such as the optic pathway, brainstem, spinal cord, and cochlea. To maximize the therapeutic ratio, accurate delineation of the target and the critical structures is necessary. With the advancement of imaging technology, the delineation of the target volumes and the critical structures for treatment planning has achieved millimeter spatial resolution. With advancements in technology, such as the multileaf collimation, 3-dimensional (3-D) radiation therapy, intensity-modulated radiation treatment (IMRT), and image-guided radiation therapy, the delivery of radiation dose is now at millimeter precision. Image-guided radiation therapy uses techniques to verify the location of the tumor or target volume before each treatment. With an increased accuracy in treatment delivery, radiation margins surrounding the target can be decreased, increasing the therapeutic ratio.
Molecular and functional characterisation of resilin across three insect orders.

R. Lyons,Darren C. C. Wong,Misook Kim,Nicolas Lekieffre,M. Huson,T. Vuocolo,D. Merritt,K. Nairn,D. Dudek,M. Colgrave,C. Elvin

DOI: https://doi.org/10.1016/j.ibmb.2011.08.002

IF: 4.421

2011-11-01

Insect Biochemistry and Molecular Biology

Abstract:
Abstract 125: Development of humanized VEGFA models to assess preclinical efficacy of novel therapeutics in vivo

Shujin Zhang,Chonghui Liu,Jin Guo,Zhiyuan Shen,James Jin,Bahetiyaer Huwatibieke,Yang Shen

DOI: https://doi.org/10.1158/1538-7445.am2024-125

IF: 11.2

2024-03-23

Cancer Research

Abstract:VEGFA is an essential growth factor required for angiogenesis in the context of normal wound healing as well as malignant tissue growth, ultimately facilitating the delivery of oxygen and nutrients to fuel cellular survival, expansion, and repair. VEGFA signaling has also been reported to exert effects on cancer cells and immune cells directly, with evidence suggesting that the pathway can both support tumor growth and inhibit immune surveillance. Thus, targeting VEGFA has been intensely explored as a therapeutic strategy for several cancer indications. Here, we generated a novel humanized VEGFA model (B-hVEGFA mice) to explore the ability of novel VEGFA-targeting therapeutics to curb cancer cell growth and angiogenesis in vivo. This was achieved by replacing the murine Vegfa gene with the corresponding human VEGFA coding region. We confirmed exclusive expression of human VEGF in lung homogenates of the humanized model at levels comparable to murine VEGF quantified in wild-type C57BL/6 mice. Immunohistochemical analysis at 8 weeks of age demonstrates no significant difference in the CD31+ area in several organs of the humanized mice when compared to wild-type C57BL/6 mice, including kidney, heart, liver, and eye. To assess the functional utility of this model in evaluating VEGFA modulators, tumor studies were conducted: murine colon cancer MC38 cells that were also engineered to express VEGFA in a similar manner (B-hVEGFA MC38 cells) were subcutaneously implanted into homozygous B-hVEGFA mice. Treatment with bevacizumab analog essentially abolished tumor growth in the humanized mice, while control tumors continued to expand over the 3 week study. To further evaluate the role of novel combination therapies or bispecific antibodies targeting VEGFA and PD-1, we also generated a triple humanized model expressing human VEGF, PD-1, and PD-L1 (B-hPD-1/hPD-L1/hVEGFA mice) by crossing B-hVEGFA mice with our B-hPD-1/hPD-L1 mice model, which expresses the extracellular domains of human PD-1 and PD-L1. Flow cytometric analysis of this model is currently underway to validate the model for further efficacy testing. Together, these humanized VEGF models provide robust in vivo platforms to evaluate novel VEGFA therapeutic candidates. Citation Format: Shujin Zhang, Chonghui Liu, Jin Guo, Zhiyuan Shen, James Jin, Bahetiyaer Huwatibieke, Yang Shen. Development of humanized VEGFA models to assess preclinical efficacy of novel therapeutics in vivo [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 125.

oncology
A Non-immunogenic Bivalent d -Protein Potently Inhibits Retinal Vascularization and Tumor Growth

Paul S. Marinec,Kyle E. Landgraf,Maruti Uppalapati,Gang Chen,Daniel Xie,Qiyang Jiang,Yanlong Zhao,Annalise Petriello,Kurt Deshayes,Stephen B. H. Kent,Dana Ault-Riche,Sachdev S. Sidhu

DOI: https://doi.org/10.1021/acschembio.1c00017

IF: 4.634

2021-02-23

ACS Chemical Biology

Abstract:We report a general approach to engineering multivalent d-proteins with antibody-like activities in vivo. Mirror-image phage display and structure-guided design were utilized to create a d-protein that uses receptor mimicry to antagonize vascular endothelial growth factor A (VEGF-A). Selections against the d-protein form of VEGF-A using phage-displayed libraries of two different domain scaffolds yielded two proteins that bound distinct receptor interaction sites on VEGF-A. X-ray crystal structures of the d-protein/VEGF-A complexes were used to guide affinity maturation and to construct a heterodimeric d-protein VEGF-A antagonist with picomolar activity. The d-protein VEGF-A antagonist prevented vascular leakage in a rabbit eye model of wet age-related macular degeneration and slowed tumor growth in the MC38 syngeneic mouse tumor model with efficacies comparable to those of approved antibody drugs, and in contrast with antibodies, the d-protein was non-immunogenic during treatment and following subcutaneous immunizations.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acschembio.1c00017?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acschembio.1c00017</a>.Methods, supporting figures, and supporting tables (<a class="ext-link" href="/doi/suppl/10.1021/acschembio.1c00017/suppl_file/cb1c00017_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

biochemistry & molecular biology
Expression and purification of functional PDGF receptor beta

Qingbin Shang,Liang Zhao,Xiaojing Wang,Meimei Wang,Sen-Fang Sui,Li-Zhi Mi

DOI: https://doi.org/10.1016/j.bbrc.2017.05.091

IF: 3.1

2017-01-01

Biochemical and Biophysical Research Communications

Abstract:Platelet Derived Growth Factor receptors (PDGFRs), members of receptor tyrosine kinase superfamily, play essential roles in early hematopoiesis, angiogenesis and organ development. Dysregulation of PDGF receptor signaling under pathological conditions associates with cancers, vascular diseases, and fibrotic diseases. Therefore, they are attractive targets in drug development. Like any other membrane proteins with a single-pass transmembrane domain, the high-resolution structural information of the full-length PDGF receptors is still not resolved. It is caused, at least in part, by the technical challenges in the expression and purification of the functional, full-length PDGF receptors. Herein, we reported our experimental details in expression and purification of the full-length PDGFRβ from mammalian cells. We found that purified PDGFRβ remained in two different oligomeric states, presumably the monomer and the dimer, with basal kinase activity in detergent micelles. Addition of PDGF-B promoted dimerization and elevated kinase activity of the receptor, suggesting that purified receptors were functional.
Expression of human vascular endothelial growth factor receptor Flt-1 extracellular domain 1-3 loop cDNA in Pichia pastoris, purification of the expressed product and detection of its biological activity.

L Ma,X N Wang,Z Q Zhang,X M Zhou,G F Zeng,A J Chen

IF: 2.831

2001-01-01

Biomedical and Environmental Sciences

Abstract:Objective To express human vascular endothelial growth factor receptor Flt-1 extracellular domain 1-3 loop cDNA in Pichia. pastroris, and to purify the expressed product and detect its biological activity. Methods By inserting human Flt-1 ( 1-3 loop) cDNA coding 316 amino acid residues into Pichia pastoris expression vector pPIC9K containing AOX1 promoter and the sequences of a secreting signal peptides, a recombinant expression plasmid pPIC9K/Flt-1 (1-3) was constructed and transformed to yeast host strain GS115, then His(+) Mut(9) phenotype transformant was screened out and cultured in flasks, and Flt-1 ( 1-3) was expressed under the induction of 1% methanol. Results SDS-PAGE showed that after being induced with 1% methanol for 4d, the expressed product existed in supernatant in the form of soluble molecule and contained 60% of total protein expressed. Western blot showed good antigenicity and specificity of expressed product. After being purified by CM-Sepharose FF and Sephacryl S-100 chromatography, the purity of the expressed product reached above 90%. Biological assay proved that the expressed product could bind to hVEGF(165) and inhibit the proliferation of HUVEC stimulated by hVEGF(165). Conclusion Human vascular endothelial growth factor receptor Flt-1 extracellular domain 1-3 loop was successfully expressed. The study lays a foundation for further application of the expressed product in the treatment of vasoformation related diseases, such as tumor and diabetic retinopathy.
Targeting angiogenic growth factors using therapeutic glycosaminoglycans on doppel-expressing endothelial cells for blocking angiogenic signaling in cancer

Jeong Uk Choi,Xiaojun Zhang,Md Mahedi Hasan,Mazharul Karim,Seung Woo Chung,Farzana Alam,Faleh Alqahtani,Sireesha Y Reddy,In-San Kim,Taslim A Al-Hilal,Youngro Byun,Sireesha Y. Reddy,Taslim A. Al-Hilal

DOI: https://doi.org/10.1016/j.biomaterials.2022.121423

IF: 14

2022-04-01

Biomaterials

Abstract:Growth factors (GF) regulate normal development to cancer progression. GFs interact with extracellular matrix (ECM) biomolecules, such as heparin sulfate (HS) glycosaminoglycan (GAG), to enhance their stability and angiogenic signaling. Biomaterials that modulate GF activity by mimicking interactions observed in the native ECM could be designed as an effective treatment strategy. However, these materials failed to attenuate angiogenic signaling site-specifically without sparing normal tissues. In this work, we investigated the effect of a GAG-based biomaterial, which binds to the tumor endothelial cells (TEC), on the interaction among vascular endothelial growth factor (VEGF), its receptors-VEGFR2 and HS-and angiogenesis. Heparin-bile acid based conjugates, as ECM-mimicking component, were synthesized to selectively target the TEC marker doppel and doppel/VEGFR2 axis. The most effective compound LHbisD4 (low molecular weight heparin conjugated with 4 molecules of dimeric dexocholic acid) reduced tumor volume concentrated over doppel-expressing EC, and decreased tumor-interstitial VEGF without affecting its plasma concentration. Doppel-destined LHbisD4 captured VEGF, formed an intermediate complex with doppel, VEGFR2, and VEGF but did not induce active VEGFR2 dimerization, and competitively inhibited HS for VEGF binding. We thus show that GAG-based materials can be designed to imitate and leverage to control tumor microenvironment via bio-inspired interactions.

engineering, biomedical,materials science, biomaterials
Inverse Problems: Making the Unseen Visible with Mathematics

M. Kaasalainen,L. Päivärinta

Abstract:
Structure and Function of Vascular Endothelial Growth Factor and Its Related Proteins

X Pan,GW Cao,CW Ke,X He,ZT Qi

1999-01-01

Abstract:Vascular endothelial growth factor(VEGF) is a highly specific mitogen promoting the formation of blood vessels in embryogenesis and wound healing. It is also a potent inducer of vascular permeability. It is a member of the cystine knot growth factor superfamily. A detailed structural and functional characterization of the interactions between VEGF and its receptors is a prerequisite for the design of molecule antagonists. These structural characterizations and biological properties make VEGF an important research object in the fields of neovascularization of ischemia tissues, prognosis of cancers, tumor metastasis, and the gene therapy.
Design and In Silico Evaluation of a Novel Cyclic Disulfide-Rich anti-VEGF Peptide as a Potential Antiangiogenic Drug

Roghayyeh Baghban,Samaneh Ghasemali,Safar Farajnia,Reyhaneh Hoseinpoor,Sahar Andarzi,Mostafa Zakariazadeh,Habib Zarredar

DOI: https://doi.org/10.1007/s10989-021-10250-8

2021-07-27

International Journal of Peptide Research and Therapeutics

Abstract:The vascular endothelial growth factor (VEGF) signaling pathway has a crucial role in regulating tumor angiogenesis. VEGF-A shows prominent interaction with the VEGF receptor-1 and VEGF receptor-2 on the membrane of the endothelial cells. The current study aimed to design and model an anti-VEGF peptide based on VEGFR2 binding regions. The effective amino acid sequences in the interaction of VEGF-A and VEGFR-2 were investigated using Chimera, SPDBV and PyMOL software. The VEGF binding sites on the receptor were determined and used as the basis for peptide design. This sequence was then subjected to random mutagenesis, and the binding affinity of resultant peptides analyzed by Hex 8.0.0 and ClusPro software. Then, GROMACS v5.0.6 has been used for Molecular Dynamics (MD) simulation and assessing the stability of target-ligand complexes. Finally, the chosen peptide with the highest affinity was grafted into two loops of SFTI-1 (sunflower trypsin inhibitor-1) and MCoTI-II (Momordica cochinchinensis trypsin inhibitor-II) frameworks for improving the peptide stability. Among the 18 peptides from the second library, four peptides were opted, of which NGIDFNRDKFLFL showed the highest affinity with a total energy of − 742 kcal/mol. We found that this peptide can bond to the VEGF and block VEGF binding to VEGFR2. The RMSD, RMSF, and H-bonds analysis verified the docking results. The peptide grafted into loop 1 of SFTI-1 increased the peptide-VEGF binding affinity compared to peptide alone. The results showed that in silico design could be used for the identification of efficient anti-angiogenic peptides for potential application in antiangiogenic therapies.
Breviscapine alleviates hepatic injury and inhibits PKC-mRNA and its protein expression in brain-dead BA-Ma mini pigs.

Shui-Jun Zhang,Yan-xia Song,W. Zhai,Ji‐Hua Shi,Liu-shun Feng,Yong-fu Zhao,Shi Chen

IF: 3.355

2007-12-15

Hepatobiliary & Pancreatic Diseases International

Abstract:BACKGROUND Brain-dead donors are the main sources for organ transplantation, but many studies show that brain-death affects the organ's function after transplantation. This study was undertaken to investigate liver injury after brain-death in BA-Ma mini pigs and the protective effects of breviscapine on hepatic function and on PKC-alpha mRNA and its protein expression. METHODS Fifteen BA-Ma mini pigs were equally divided into 3 groups at random: brain-dead (group B), breviscapine pretreated (group P), and control (group C). The brain-dead model was established by increasing intracranial pressure in a modified, slow and intermittent way. At 3, 6, 12, 18 and 24 hours after the initial brain-death, the levels of serum AST, ALT, TNF-alpha, IL-1beta, and IL-6 were determined. The changes in hepatic tissues were assessed, and the expression of PKC-alpha and PKC-alpha mRNA was detected by immunohistochemistry and RT-PCR, respectively. RESULTS The levels of AST and ALT in groups B and P began to increase 12 hours after brain-death, while the values in group P were lower than those in group B (P<0.05). The levels of IL-1beta, IL-6, and TNF-alpha in groups B and P at 3, 6, 12 and 18 hours were lower than those in group B (P<0.05). At 6, 12 and 24 hours, the expressions of PKC-alpha mRNA and PKC-alpha protein in group P were lower than those in group B (P<0.05). The degree of injury to hepatic cells in group P was milder than that in group B. CONCLUSIONS Breviscapine inhibits the degree of PKC-alpha mRNA transcription and its protein translation, decreases the release of inflammatory factors, and thus alleviates hepatic injury during brain-death.
Sustained delivery of vascular endothelial growth factor using a dextran/poly(lactic-co-glycolic acid)-combined microsphere system for therapeutic neovascularization

Zhen Dong Zhang,Ying Qi Xu,Feng Chen,Jun Fu Luo,Chong Dong Liu

DOI: https://doi.org/10.1007/s00380-018-1230-5

2018-07-24

Heart and Vessels

Abstract:We hypothesize that the controlled delivery of vascular endothelial growth factor (VEGF) using a novel protein sustained-release system based on the combination of protein-loaded dextran microparticles and PLGA microspheres could be useful to achieve mature vessel formation in a rat hind-limb ischemic model. VEGF-loaded dextran microparticles were fabricated and then encapsulated into poly(lactic-co-glycolic acid) (PLGA) microspheres to prepare VEGF–dextran–PLGA microspheres. The release behavior and bioactivity in promoting endothelial cell proliferation of VEGF from PLGA microspheres were monitored in vitro. VEGF–dextran–PLGA microsphere-loaded fibrin gel was injected into an ischemic rat model, and neovascularization at the ischemic site was evaluated. The release of VEGF from PLGA microspheres was in a sustained manner for more than 1 month in vitro with low level of initial burst release. The released VEGF enhanced the proliferation of endothelial cells in vitro, and significantly promoted the capillaries and smooth muscle α-actin positive vessels formation in vivo. The retained bioactivity of VEGF released from VEGF–dextran–PLGA microspheres potentiated the angiogenic efficacy of VEGF. This sustained-release system may be a promising vehicle for delivery of multiple angiogenic factors for therapeutic neovascularization.

cardiac & cardiovascular systems,peripheral vascular disease
Urodynamics following radical abdominal hysterectomy for cervical cancer

G. Ralph,Karl Tamussino,W. Lichtenegger

DOI: https://doi.org/10.1007/BF00932270

Archives of Gynecology and Obstetrics

Abstract:
Decreased basal chloride secretion and altered cystic fibrosis transmembrane conductance regulatory protein, Villin, GLUT5 protein expression in jejunum from leptin-deficient mice

Lana Leung,Jonathan Kang,Esa Rayyan,Ashesh Bhakta,B. Barrett,David Larsen,Ryan Jelinek,J. Willey,S. Cochran,T. Broderick,L. Al-Nakkash

DOI: https://doi.org/10.2147/DMSO.S63714

2014-07-21

Abstract:Patients with diabetes and obesity are at increased risk of developing disturbances in intestinal function. In this study, we characterized jejunal function in the clinically relevant leptin-deficient ob/ob mouse, a model of diabetes and obesity. We measured transepithelial short circuit current (Isc), across freshly isolated segments of jejunum from 12-week-old ob/ob and lean C57BL/6J (female and male) mice. The basal Isc was significantly decreased (~30%) in the ob/ob mice (66.5±5.7 μA/cm2 [n=20]) (P< 0.05) compared with their lean counterparts (95.1±9.1 μA/cm2 [n=19]). Inhibition with clotrimazole (100 μM, applied bilaterally) was significantly reduced in the ob/ob mice (−7.92%±3.67% [n=15]) (P<0.05) compared with the lean mice (10.44%±7.92% [n=15]), indicating a decreased contribution of Ca2+-activated K+ (KCa) channels in the ob/ob mice. Inhibition with ouabain (100 μM, applied serosally) was significantly reduced in the ob/ob mice (1.40%±3.61%, n=13) (P< 0.05) versus the lean mice (18.93%±3.76% [n=18]), suggesting a potential defect in the Na+/K+-adenosine triphosphate (ATP)ase pump with leptin-deficiency. Expression of cystic fibrosis transmembrane conductance regulatory protein (CFTR) (normalized to glyceraldehyde-3-phosphate dehydrogenase [GAPDH]) was significantly decreased ~twofold (P<0.05) in the ob/ob mice compared with the leans, whilst crypt depth was unchanged. Villi length was significantly increased by ~25% (P<0.05) in the ob/ob mice compared with the leans and was associated with an increase in Villin and GLUT5 expression. GLUT2 and SGLT-1 expression were both unchanged. Our data suggests that reduced basal jejunal Isc in ob/ob mice is likely a consequence of reduced CFTR expression and decreased activity of the basolateral KCa channel and Na+/K+-ATPase. Understanding intestinal dysfunctions in ob/ob jejunum may allow for the development of novel drug targets to treat obesity and diabetes.
Framework Nucleic Acids‐Based VEGF Signaling Activating System for Angiogenesis: A Dual Stimulation Strategy

Yichen Ge,Qingxuan Wang,Yangxue Yao,Qin Xin,Jiafei Sun,Wen Chen,Yunfeng Lin,Xiaoxiao Cai

DOI: https://doi.org/10.1002/advs.202308701

IF: 15.1

2024-03-11

Advanced Science

Abstract:Angiogenesis is crucial for tissue engineering, wound healing, and regenerative medicine. Here, a framework nucleic acid‐based nanomaterial is synthesized by combining tFNAs, DNA aptamer Apt02, and DMOG to enhance angiogenesis through upregulating the VEGF/VEGFR and HIF signaling in vitro and in vivo. Angiogenesis is crucial for tissue engineering, wound healing, and regenerative medicine. Nanomaterials constructed based on specific goals can be employed to activate endogenous growth factor‐related signaling. In this study, based on the conventional single‐stranded DNA self‐assembly into tetrahedral framework nucleic acids (tFNAs), the Apt02 nucleic acid aptamer and dimethyloxallyl glycine (DMOG) small molecule are integrated into a complex via a template‐based click chemistry reaction and toehold‐mediated strand displacement reaction. Thus, being able to simulate the VEGF (vascular endothelial growth factor) function and stabilize HIF (hypoxia‐inducible factor), a functional whole is constructed and applied to angiogenesis. Cellular studies demonstrate that the tFNAs‐Apt02 complex (TAC) has a conspicuous affinity to human umbilical vein endothelial cells (HUVECs). Further incubation with DMOG yields the tFNAs‐Apt02‐DMOG complex (TACD), which promotes VEGF secretion, in vitro blood vessel formation, sprouting, and migration of HUVECs. Additionally, TACD enhances angiogenesis by upregulating the VEGF/VEGFR and HIF signaling pathways. Moreover, in a diabetic mouse skin defect repair process, TACD increases blood vessel formation and collagen deposition, therefore accelerating wound healing. The novel strategy simulating VEGF and stabilizing HIF promotes blood‐vessel formation in vivo and in vitro and has the potential for broad applications in the vascularization field.

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
Structure elucidation and immunological activity of a novel glycopeptide from mannatide.

Yanhong Shen,Mengqi Wu,Zhizhen Xu,Yanfei Wan,Li Zhang,Wenqing Zhang,W. Xia

DOI: https://doi.org/10.1016/j.ijbiomac.2017.02.003

IF: 8.2

2017-06-01

International Journal of Biological Macromolecules

Abstract:
3D physiologically-informed deep learning for drug discovery of a novel vascular endothelial growth factor receptor-2 (VEGFR2)

Mengyang Xu,Xiaoyue Xiao,Yinglu Chen,Xiaoyan Zhou,Luca Parisi,Renfei Ma

DOI: https://doi.org/10.1016/j.heliyon.2024.e35769

IF: 3.776

2024-08-08

Heliyon

Abstract:Angiogenesis is an essential process in tumorigenesis, tumor invasion, and metastasis, and is an intriguing pathway for drug discovery. Targeting vascular endothelial growth factor receptor 2 (VEGFR2) to inhibit tumor angiogenic pathways has been widely explored and adopted in clinical practice. However, most drugs, such as the Food and Drug Administration -approved drug axitinib (ATC code: L01EK01), have considerable side effects and limited tolerability. Therefore, there is an urgent need for the development of novel VEGFR2 inhibitors. In this study, we propose a novel strategy to design potential candidates targeting VEGFR2 using three-dimensional (3D) deep learning and structural modeling methods. A geometric-enhanced molecular representation learning method (GEM) model employing a graph neural network (GNN) as its underlying predictive algorithm was used to predict the activity of the candidates. In the structural modeling method, flexible docking was performed to screen data with high affinity and explore the mechanism of the inhibitors. Small -molecule compounds with consistently improved properties were identified based on the intersection of the scores obtained from both methods. Candidates identified using the GEM-GNN model were selected for in silico modeling using molecular dynamics simulations to further validate their efficacy. The GEM-GNN model enabled the identification of candidate compounds with potentially more favorable properties than the existing drug, axitinib, while achieving higher efficacy.
Screening and Characterization of Inhibiting Peptides Binding to the Tumor Vascular Growth Factor Receptor

Xiang Jin,Jinghe Huang,Zhong Zhendong,Yang Huang,Zheng Xiang

2004-01-01

Abstract:Objective To screen the phage-epitope library to predict the receptor recognition site on VEGF,identify peptide that is able to block the interaction of VEGF-KDR and to find a potent vaccine against tumor angiogenesis through targeting VEGF. Methods Two phage-epitope libraries were screened with two anti-VEGF neutralizing monoclonal antibodies JH121 and VG189. The clones were tested by Dot blot and the positive clones were used to immunize mice. The serum, phage peptides and 7-mer peptide(GWYYDAL) were added to measure their effects on the growth of HUVEC(human umbilical vascular endothelial cell). Results All the selected clones gave strong signal in Dot blot. The 7-mer peptide and 12-mer peptide selected from the peptide library elicited strong anti-VEGF antibody immuno-reaction in mice. The antibody induced by peptide GWYYDAVL abolished VEGF-induced HUVEC growth. Moreover, the peptide GWYYDAL, VASAVFYSALVE displaying on phage and the synthetic peptide, also inhibited the growth of HUVEC. Conclusion Our results suggested that the two peptides GWYYDAL and VASAVFYSALVE were both effective mimickers of VEGF and might function as potent inhibitors of KDR.

Effects of ions on thyrotrophin and prostaglandin E stimulation of glucose oxidation and adenyl cyclase-cyclic AMP system in dog thyroid slices.

[Expression of Human VEGF165 Gene in Rat Bone Marrow Stromal Cells in Vitro].

Cracking the ENCODE: From transcription to therapeutics

Tumor Imaging: Radiation Oncology Perspective

Molecular and functional characterisation of resilin across three insect orders.

Abstract 125: Development of humanized VEGFA models to assess preclinical efficacy of novel therapeutics in vivo

A Non-immunogenic Bivalent d -Protein Potently Inhibits Retinal Vascularization and Tumor Growth

Expression and purification of functional PDGF receptor beta

Expression of human vascular endothelial growth factor receptor Flt-1 extracellular domain 1-3 loop cDNA in Pichia pastoris, purification of the expressed product and detection of its biological activity.

Targeting angiogenic growth factors using therapeutic glycosaminoglycans on doppel-expressing endothelial cells for blocking angiogenic signaling in cancer

Inverse Problems: Making the Unseen Visible with Mathematics

Structure and Function of Vascular Endothelial Growth Factor and Its Related Proteins

Design and In Silico Evaluation of a Novel Cyclic Disulfide-Rich anti-VEGF Peptide as a Potential Antiangiogenic Drug

Breviscapine alleviates hepatic injury and inhibits PKC-mRNA and its protein expression in brain-dead BA-Ma mini pigs.

Sustained delivery of vascular endothelial growth factor using a dextran/poly(lactic-co-glycolic acid)-combined microsphere system for therapeutic neovascularization

Urodynamics following radical abdominal hysterectomy for cervical cancer

Decreased basal chloride secretion and altered cystic fibrosis transmembrane conductance regulatory protein, Villin, GLUT5 protein expression in jejunum from leptin-deficient mice

Framework Nucleic Acids‐Based VEGF Signaling Activating System for Angiogenesis: A Dual Stimulation Strategy

Structure elucidation and immunological activity of a novel glycopeptide from mannatide.

3D physiologically-informed deep learning for drug discovery of a novel vascular endothelial growth factor receptor-2 (VEGFR2)

Screening and Characterization of Inhibiting Peptides Binding to the Tumor Vascular Growth Factor Receptor